STOCK TITAN
  1. Home
  2. News
  3. ANGO

AngioDynamics, Inc. - ANGO STOCK NEWS

Welcome to our dedicated page for AngioDynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on AngioDynamics stock.

Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices that serve interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The company's product portfolio includes market-leading systems such as the NanoKnife® system, radiofrequency ablation devices, and a variety of vascular access, angiographic, dialysis, angioplasty, and embolization products.

AngioDynamics has a strong track record of developing and bringing new technologies to market, maintaining a dynamic presence in the high-growth medical device industry. Recently, the company reported net sales of $78.7 million for the first quarter of fiscal year 2024, including a 13.3% increase in Med Tech net sales driven by the NanoKnife platform. AngioDynamics also completed the sale of its Dialysis and BioSentry Biopsy Tract Sealant System businesses, significantly enhancing its financial flexibility.

In addition to financial growth, AngioDynamics continues to innovate with significant developments such as the APEX-AV study, aimed at evaluating the safety and efficacy of the AlphaVac F1885 System for treating acute pulmonary embolism. The company’s AlphaVac F1885 System has recently received FDA clearance for the treatment of pulmonary embolism, a significant milestone that expands its indication in critical medical scenarios.

With ongoing plans to transition to a fully outsourced manufacturing model and recent divestitures to streamline its portfolio, AngioDynamics is well-positioned to focus on its core strengths and drive long-term profitability. The company's net sales are projected to be between $328 to $333 million for fiscal year 2024, with an anticipated improved gross margin and reduced adjusted loss per share.

News

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced net sales of $79.1 million for the second quarter of fiscal year 2024, with a 2.7% increase on a pro-forma basis compared to the prior-year quarter. The company reported a GAAP loss per share of $0.72 and adjusted loss per share of $0.05. Cash and cash equivalents at November 30, 2023, were $60.9 million. The company expects to achieve full-year adjusted EPS profitability in FY27.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.87%
Tags
earnings
-
News

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, and EVP and CFO, Stephen Trowbridge, will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 11, 2024. The presentation will focus on the company's medical technology innovations and cancer treatment advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
-
News

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) will report financial results for Q2 of fiscal year 2024 on January 5, 2024. The management will host a conference call to discuss the results, accessible via phone or webcast. The webcast replay and call recording will also be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
News

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism

Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) has completed the patient enrollment in the APEX-AV study, evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for treating acute intermediate-risk pulmonary embolism (PE). The study enrolled 122 patients across 25 hospital-based sites in the US, with a focus on reducing thrombus burden and improving right ventricular function. The primary efficacy and safety endpoints of the study are the reduction in RV/LV ratio and the rate of Major Adverse Events (MAEs) within the first 48 hours post-procedure. The study aims to broaden the treatment options for PE, which affects around 900,000 people in the US every year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
none
-
News

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

Rhea-AI Summary
AngioDynamics, Inc. reports Q1 FY2024 financial results with net sales of $78.7 million, a 5.7% increase excluding Dialysis and BioSentry sales. Med Tech net sales increased 13.3% to $25.9 million. Gross margin declined 20 basis points to 50.9% on a pro-forma basis. Completed sale of Dialysis and BioSentry businesses for $100 million. Adjusted loss per share of $0.12. Cash and cash equivalents at $57.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
earnings
-
News

AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023

Rhea-AI Summary
AngioDynamics, Inc. will report Q1 FY2024 financial results on October 4, 2023, before market open. Conference call scheduled at 8:00 a.m. ET to discuss results. Webcast available on company website. Recording of call available until October 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences earnings
News

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Rhea-AI Summary
AngioDynamics receives FDA Breakthrough Device designation for AngioVac System's non-surgical removal of vegetation from the right heart.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
News

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
clinical trial
-
News

AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference

Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) to participate in fireside chat at Canaccord Genuity 43rd Annual Growth Conference. The company's President and CEO, Jim Clemmer, and CFO, Stephen Trowbridge, will discuss the latest developments in medical technology and cancer treatment options. The live webcast will be accessible through the 'Investors' section of the company's website at www.angiodynamics.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
News

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

Rhea-AI Summary
AngioDynamics, Inc. has announced the appointment of Lorinda Burgess to its Board of Directors. Ms. Burgess brings over 35 years of management and financial experience, including over 15 years at Medtronic, Inc. She has a track record of driving growth and profitability through transformative strategies. AngioDynamics aims to become a profitable, high-growth medical technology company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
management

FAQ

What is the current stock price of AngioDynamics (ANGO)?

The current stock price of AngioDynamics (ANGO) is $8.89 as of December 20, 2024.

What is the market cap of AngioDynamics (ANGO)?

The market cap of AngioDynamics (ANGO) is approximately 357.2M.

What does AngioDynamics, Inc. specialize in?

AngioDynamics, Inc. specializes in providing innovative medical devices that assist in the minimally invasive treatment of cancer and peripheral vascular disease.

What are some recent achievements of AngioDynamics, Inc.?

Recent achievements include a 13.3% increase in Med Tech net sales, the sale of its Dialysis and BioSentry Biopsy Tract Sealant System businesses, and FDA clearance of the AlphaVac F1885 System for treating pulmonary embolism.

What is the AlphaVac F1885 System?

The AlphaVac F1885 System is a medical device designed for the non-surgical removal of thrombi or emboli from the venous system, recently cleared by the FDA for treating pulmonary embolism.

What financial performance did AngioDynamics report for the first quarter of fiscal year 2024?

AngioDynamics reported net sales of $78.7 million for the first quarter of fiscal year 2024, including a 13.3% increase in Med Tech net sales.

What are AngioDynamics' future plans for manufacturing?

AngioDynamics plans to transition to a fully outsourced manufacturing model, which is expected to reduce expenses and improve profitability by fiscal year 2027.

Where does AngioDynamics generate the majority of its revenue?

AngioDynamics generates the majority of its revenue from the United States.

What is the NanoKnife® system?

The NanoKnife® system is one of AngioDynamics' market-leading technologies, used for the irreversible electroporation (IRE) treatment of soft tissue.

How does AngioDynamics plan to enhance its focus on core strengths?

AngioDynamics is focusing on its core strengths by divesting non-core assets, such as the Dialysis and BioSentry Biopsy Tract Sealant System businesses, and streamlining its product portfolio.

What is the APEX-AV study?

The APEX-AV study is an investigational device exemption study conducted by AngioDynamics to evaluate the safety and efficacy of the AlphaVac F1885 System in treating acute intermediate-risk pulmonary embolism.

How does AngioDynamics contribute to the medical device industry?

AngioDynamics contributes to the medical device industry by continuously developing and bringing to market innovative technologies and solutions that improve patient outcomes and expand treatment options.

Stock ANGO logo
AngioDynamics, Inc.

Nasdaq:ANGO

ANGO Rankings

#3381 Ranked by Market Cap
N/A Ranked by Dividends

ANGO Stock Data

357.18M
38.36M
5.61%
81.33%
2.79%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
LATHAM